Medications for Bardet-Biedl Syndrome
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Bardet-Biedl Syndrome.
Found 1 Approved Drug for Bardet-Biedl Syndrome
Imcivree
Generic Name
Setmelanotide
Imcivree
Generic Name
Setmelanotide
Form: Solution
Method of administration: Subcutaneous
FDA approval date: December 14, 2020
Classification: Melanocortin 4 Receptor Agonist
IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to: Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances